Lantern Pharma Inc. (LTRN) Earnings Call Transcripts
Lantern Pharma Inc.'s Latest Earnings Call - April 9, 2026
In the first quarter of fiscal year 2026, Lantern Pharma Inc. (LTRN:US) unveiled its next-generation withZeta AI platform, focusing on rare cancers. The management emphasized the platform's ability to generate new scientific knowledge and improve drug development efficiency. Although specific revenue figures were not disclosed, management indicated that AI revenue is already being generated, and they expect significant growth following the platform's full launch. The company is optimistic about its future prospects, especially with upcoming presentations at major conferences.
Reported metrics
| Metric | Value |
|---|---|
| AI Revenue | null (null) |
| Rare Cancer Areas Targeted | 438 (positive) |
| Time Efficiency | minutes (positive) |
| Upcoming Conference | American Association of Cancer Research (positive) |
| Subscription Plans | null (null) |
| Future Enhancements | null (positive) |
Guidance from management
Management expressed optimism about future growth driven by the withZeta platform and its upcoming launch at major conferences, although specific financial guidance was not provided.
What management said
41 in this case. So those are all the external resources that it's querying. That's going to be the list of clinical trials that it's referenced, PubMed articles that it's found the abstract for and DOIs. And then additionally, if you wanted to see other internal proprietary databases and AI modules that were queried you could go into the research queries and see exactly what tools were executed in this process.
Yes. And then this is [indiscernible] it's including it, recent failed approaches. That's great. So let's say -- let's look at one of these in detail. In fact, this is a great place maybe for Zeta to say, I'm missing something, right?
What analysts pressed on
Analysts raised questions about the profitability of AI tokens and the current subscription revenue. There is concern regarding the cost management of AI operations and how it will impact overall profitability as the platform scales.
Main topics on the call
- Launch of withZeta AI Platform — Management described the withZeta AI platform as a revolutionary tool for drug development, particularly for rare cancers, stating it has 'the ability to reason' and 'generate net new scientific knowledge.' This position...
- Focus on Rare Cancers — The company highlighted its commitment to rare cancers, noting that there are 'over 438 rare cancer areas' they aim to conquer, which reflects a strategic focus on high unmet medical needs.
- AI Revenue Generation — Management confirmed that they are already generating AI revenue, although specific figures were not provided. They expressed confidence in future growth, particularly with the upcoming launch at the American Association...
- Future Enhancements and Features — The management outlined future enhancements for the withZeta platform, including 'team workspaces, role-based access, and custom integrations,' indicating a strong roadmap for product development.
Read the full Lantern Pharma Inc. transcript (April 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Lantern Pharma Inc.
Lantern Pharma Inc. (LTRN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 34 calls on record spanning July 30, 2020 to April 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 34 Lantern Pharma Inc. earnings call transcripts on record, spanning July 30, 2020 to April 30, 2026. Based on this history, Lantern Pharma Inc. reports quarterly. The most recent call on file is dated April 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- LTRN
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 34
- First call
- July 30, 2020
- Most recent
- April 30, 2026
- Reporting cadence
- quarterly